1
|
Gadenstaetter AJ, Krumpoeck PE, Auinger AB, Yildiz E, Tu A, Matula C, Arnoldner C, Landegger LD. Prestin in Human Perilymph, Cerebrospinal Fluid, and Blood as a Biomarker for Hearing Loss. Otolaryngol Head Neck Surg 2024. [PMID: 38988299 DOI: 10.1002/ohn.895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2024] [Revised: 06/12/2024] [Accepted: 06/23/2024] [Indexed: 07/12/2024]
Abstract
OBJECTIVE Determining the concentration of prestin in human blood, cerebrospinal fluid (CSF), and perilymph (PL), and evaluating its suitability as a clinical biomarker for sensori-neural hearing loss (SNHL). STUDY DESIGN Human blood, CSF, and PL samples were intraoperatively collected from 42 patients with tumors of the internal auditory canal or with intracochlear tumors undergoing translabyrinthine or middle fossa tumor removal. Prestin concentration was measured using enzyme-linked immunosorbent assay and linear regression analyses were performed to investigate its associations with audiological as well as vestibular test results. SETTING Tertiary referral center. RESULTS The median prestin concentration in blood samples of the 42 study participants (26 women, mean ± standard deviation age, 52.7 ± 12.5 years) was 1.32 (interquartile range, IQR, 0.71-1.99) ng/mL. CSF prestin levels were significantly higher with 4.73 (IQR, 2.45-14.03) ng/mL (P = .005). With 84.74 (IQR, 38.95-122.00) ng/mL, PL prestin concentration was significantly higher compared to blood (P = .01) and CSF (P = .03) levels. Linear regression analyses showed significant associations of CSF prestin concentration with preoperative hearing levels (pure-tone average and word recognition; P = .008, R2 = 0.1894; P = .03, R2 = 0.1857), but no correlations with blood or PL levels. CONCLUSION AND RELEVANCE This study's findings highlight the volatile nature of prestin levels and provide the first insights into this potential biomarker's concentrations in body fluids apart from blood. Future investigations should comprehensively assess human prestin levels with different etiologies of SNHL, prestin's natural homeostasis and systemic circulation, and its temporal dynamics after cochlear trauma. Finally, clinically approved detection kits for prestin are urgently required prior to considering a potential translational implementation of this diagnostic technique.
Collapse
Affiliation(s)
- Anselm Joseph Gadenstaetter
- Christian Doppler Laboratory for Inner Ear Research, Department of Otorhinolaryngology-Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
- Department of Otorhinolaryngology-Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
| | - Paul Emmerich Krumpoeck
- Christian Doppler Laboratory for Inner Ear Research, Department of Otorhinolaryngology-Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
- Department of Otorhinolaryngology-Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
| | - Alice Barbara Auinger
- Department of Otorhinolaryngology-Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
| | - Erdem Yildiz
- Christian Doppler Laboratory for Inner Ear Research, Department of Otorhinolaryngology-Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
- Department of Otorhinolaryngology-Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
| | - Aldine Tu
- Department of Otorhinolaryngology-Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
| | - Christian Matula
- Department of Neurosurgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
| | - Christoph Arnoldner
- Christian Doppler Laboratory for Inner Ear Research, Department of Otorhinolaryngology-Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
- Department of Otorhinolaryngology-Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
| | - Lukas David Landegger
- Christian Doppler Laboratory for Inner Ear Research, Department of Otorhinolaryngology-Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
- Department of Otorhinolaryngology-Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
2
|
Zheng J, Zhou Y, Fuentes RJ, Tan X. Verification of Outer Hair Cell Motor Protein, Prestin, as a Serological Biomarker for Mouse Cochlear Damage. Int J Mol Sci 2024; 25:7285. [PMID: 39000390 PMCID: PMC11241755 DOI: 10.3390/ijms25137285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2024] [Revised: 06/26/2024] [Accepted: 06/27/2024] [Indexed: 07/16/2024] Open
Abstract
The motor protein prestin, found in the inner ear's outer hair cells (OHCs), is responsible for high sensitivity and sharp frequency selectivity in mammalian hearing. Some studies have suggested that prestin could be a serological biomarker for cochlear damage, as OHCs are highly vulnerable to damage from various sources. However, the reported data are inconsistent and lack appropriate negative controls. To investigate whether prestin can be used as a serological biomarker for cochlear damage or stress, we measured prestin quantities in the bloodstreams of mice using ELISA kits from different companies. Wildtype (WT) mice were exposed to different ototoxic treatments, including noise exposure and ototoxic reagents that rapidly kill OHCs. Prestin-knockout (KO) mice were used as a negative control. Our data show that some ELISA kits were not able to detect prestin specifically. The ELISA kit that could detect the prestin protein from cochlear homogenates failed to detect prestin in the bloodstream, despite there being significant damage to OHCs in the cochleae. Furthermore, the optical densities of the serum samples, which correlate to prestin quantities, were significantly influenced by hemolysis in the samples. In conclusion, Prestin from OHCs is not a sensitive and reliable serological biomarker for detecting cochlear damage in mice using ELISA.
Collapse
Affiliation(s)
- Jing Zheng
- Department of Otolaryngology-Head and Neck Surgery, Feinberg School of Medicine, Chicago Campus, Northwestern University, Chicago, IL 60611, USA; (R.J.F.); (X.T.)
- Department of Communication Sciences and Disorders, School of Communication, Evanston Campus, Northwestern University, Evanston, IL 60208, USA;
- The Knowles Hearing Center, Northwestern University, Evanston, IL 60208, USA
| | - Yingjie Zhou
- Department of Communication Sciences and Disorders, School of Communication, Evanston Campus, Northwestern University, Evanston, IL 60208, USA;
| | - Robert J. Fuentes
- Department of Otolaryngology-Head and Neck Surgery, Feinberg School of Medicine, Chicago Campus, Northwestern University, Chicago, IL 60611, USA; (R.J.F.); (X.T.)
| | - Xiaodong Tan
- Department of Otolaryngology-Head and Neck Surgery, Feinberg School of Medicine, Chicago Campus, Northwestern University, Chicago, IL 60611, USA; (R.J.F.); (X.T.)
- The Knowles Hearing Center, Northwestern University, Evanston, IL 60208, USA
| |
Collapse
|
3
|
Baskadem Yilmazer A, Tanrısever O, Alagoz MH, Yilmazer R, Goker AE, Tutar B, Uyar Y. Evaluation of inner ear damage by mastoid drilling with measurement of serum prestin (SLC26A5) levels. Braz J Otorhinolaryngol 2024; 90:101380. [PMID: 38237483 PMCID: PMC10828577 DOI: 10.1016/j.bjorl.2023.101380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Revised: 12/01/2023] [Accepted: 12/07/2023] [Indexed: 02/03/2024] Open
Abstract
OBJECTIVE The objective of this study is to demonstrate any inner ear injury caused by drilling in mastoid surgery with prestin, outer hair cell motor protein specific to the cochlea. METHODS The patients with chronic otitis media requiring mastoidectomy (n = 21) and myringoplasty (n = 21) were included. Serum prestin level obtained from blood samples was measured before surgery and on postoperative days 0, 3, and 7 using Human Prestin (SLC26A5) ELISA Kit. All patients underwent the Pure Tone Audiometry (PTA) test before surgery and on the postoperative 7th day. The drilling time was also recorded for all patients who underwent mastoidectomy. RESULTS In both mastoidectomy and myringoplasty groups, the postoperative serum prestin levels increased on days 0 and 7 (pday-0 = 0.002, pday-7 = 0.001 and pday-0 = 0.005, pday-7 = 0.001, respectively). There was no significant difference in the serum prestin levels between the two groups, postoperatively. The PTA thresholds at day 7 did not change in either group. A significant decline at 2000 Hz of bone conduction hearing threshold in both groups and a decline at 4000 Hz in the myringoplasty group were found. There was no correlation between the drilling time and the increase of prestin levels in the postoperative day 0, 3, and 7. CONCLUSION Our results showed that mastoid drilling is not related to a significant inner ear injury. Although the myringoplasty group was not exposed to drill trauma, there was a similar increase in serum prestin levels as the mastoidectomy group. Also, a significant decline at 2000 Hz of bone conduction hearing threshold in both groups and a decline at 4000 Hz in the myringoplasty group were found. These findings suggest that suction and ossicular manipulation trauma can lead to an increase in serum prestin levels and postoperative temporary or permanent SNHL at 2000 and 4000 Hz. LEVEL OF EVIDENCE Level-4.
Collapse
Affiliation(s)
- Ayca Baskadem Yilmazer
- Saglik Bilimleri University, Prof. Dr. Cemil Tascioglu Hospital, Department of Otorhinolaryngology, Head and Neck Surgery, Istanbul, Turkey.
| | - Onur Tanrısever
- Saglik Bilimleri University, Prof. Dr. Cemil Tascioglu Hospital, Department of Otorhinolaryngology, Head and Neck Surgery, Istanbul, Turkey
| | - Maide Hacer Alagoz
- Saglik Bilimleri University, Prof. Dr. Cemil Tascioglu Hospital, Department of Biochemistry, Istanbul, Turkey
| | - Rasim Yilmazer
- Saglik Bilimleri University, Dr. Lutfi Kirdar City Hospital, Department of Otorhinolaryngology, Head and Neck Surgery, Istanbul, Turkey
| | - Ayse Enise Goker
- Saglik Bilimleri University, Prof. Dr. Cemil Tascioglu Hospital, Department of Otorhinolaryngology, Head and Neck Surgery, Istanbul, Turkey
| | - Belgin Tutar
- Saglik Bilimleri University, Prof. Dr. Cemil Tascioglu Hospital, Department of Otorhinolaryngology, Head and Neck Surgery, Istanbul, Turkey
| | - Yavuz Uyar
- Saglik Bilimleri University, Prof. Dr. Cemil Tascioglu Hospital, Department of Otorhinolaryngology, Head and Neck Surgery, Istanbul, Turkey
| |
Collapse
|
4
|
Al Samarrai ARH, Mahdi BM, Parham K. Relationship of Serum Prestin Levels to the Severity of Sensorineural Hearing Loss. Cureus 2024; 16:e53763. [PMID: 38465090 PMCID: PMC10921123 DOI: 10.7759/cureus.53763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/07/2024] [Indexed: 03/12/2024] Open
Abstract
OBJECTIVE Prestin is an outer hair cell (OHC) protein responsible for increasing cochlear sensitivity and has been proposed as a biomarker. We aimed to evaluate whether the serum prestin level is related to the severity of chronic sensorineural hearing loss (SNHL). METHODS Ninety subjects were recruited from the patient base at Samarra public hospitals and clinics in Iraq from January to October of 2022. They were divided into three groups equally: a group of healthy people without hearing loss (G0), a group with moderate SNHL (G1), and a group with severe SNHL (G2). The subjects ranged from 20 to 80 years of age and included 51 males and 39 females. Blood samples were collected, then serum was separated, and enzyme-linked immunosorbent assays were performed to quantify the levels of prestin. RESULTS Hearing thresholds were sequentially statistically higher across the three groups. While prestin levels were significantly higher in G1 and G2 than that in G0, there were no differences between the G1 and G2 levels. Serum prestin levels were positively correlated with hearing thresholds in G1, but not G2. CONCLUSION Our results suggest that in the clinical setting, prestin is sensitive to chronic mild to moderate SNHL (i.e., up to 40-60 dB), not more severe loss. This range is consistent with the added sensitivity provided by OHCs in the cochlea and provides support for prestin as a biomarker of OHC-mediated SNHL.
Collapse
Affiliation(s)
| | - Bakr M Mahdi
- Department of Otolaryngology, Samarra General Hospital, Samarra, IRQ
| | - Kourosh Parham
- Department of Otolaryngology-Head and Neck Surgery, University of Connecticut Health, Farmington, USA
| |
Collapse
|
5
|
Harrison MS, Driscoll BG, Farnsworth J, Hinton A, Peppi M, McLean W, Parham K. Automated Western Blot Analysis of Ototoxin-Induced Prestin Burst in the Blood after Cyclodextrin Exposure. Otol Neurotol 2023; 44:e653-e659. [PMID: 37590840 DOI: 10.1097/mao.0000000000003994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/19/2023]
Abstract
HYPOTHESIS Ototoxin cyclodextrin (CDX) will induce a burst in serum prestin when quantified with automated Western blot analysis. BACKGROUND In the clinical realm, we primarily rely on audiological measures for diagnosis and surveillance of sensorineural hearing loss (SNHL) and have limited therapeutic options. We have proposed a blood-based biomarker approach to overcome this challenge by measuring the outer hair cell's (OHC) electromotile protein, prestin, in the blood. Previously, we demonstrated a burst in serum prestin after cisplatin exposure using enzyme-linked immunosorbent assayELISA. METHODS Guinea pigs were treated with either 3,000 or 4,000 mg/kg CDX, and serum samples were obtained through 3 days after exposure. Serum prestin levels were quantified using automated blot analysis, western and hair cell counts were obtained. RESULTS Both 3,000 and 4,000 mg/kg resulted in robust OHC loss, although more variability was seen at the lower dose. Automated Western blot analysis demonstrated that the prestin profile after CDX exposure is different than baseline. Specifically, a new ~134- kDa band accounted for the prestin burst after ototoxin ablation of OHCs at both doses. CONCLUSIONS We reproduced the prestin burst seen after cisplatin administration using CDX. Automated Western blot western analysis revealed that a ~a ~ 134- kDa species of prestin is responsible for the burst. We suggest that the induced band may be a prestin dimer, which could serve as a biomarker for early detection of ototoxicity in the clinical setting. These results add further promise to the potential of serum prestin to serve as an ototoxicity biomarker when using therapeutics with ototoxic properties.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Kourosh Parham
- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Connecticut School of Medicine, Farmington, Connecticut
| |
Collapse
|
6
|
Brutnell TP, Wang X, Bao J. Integrating pharmacogenomics into clinical trials of hearing disorders. THE JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA 2022; 152:2828. [PMID: 36456290 PMCID: PMC9648993 DOI: 10.1121/10.0015092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 09/26/2022] [Accepted: 10/20/2022] [Indexed: 06/17/2023]
Abstract
In 2019, the U.S. Food and Drug Administration issued guidance to increase the efficiency of drug development and support precision medicine, including tailoring treatments to those patients who will benefit based on genetic variation even in the absence of a documented mechanism of action. Although multiple advancements have been made in the field of pharmacogenetics (PGx) for other disease conditions, there are no approved PGx guidelines in the treatment of hearing disorders. In studies of noise-induced hearing loss (NIHL), some progress has been made in the last several years associating genomic loci with susceptibility to noise damage. However, the power of such studies is limited as the underlying physiological responses may vary considerably among the patient populations. Here, we have summarized previous animal studies to argue that NIHL subtyping is a promising strategy to increase the granularity of audiological assessments. By coupling this enhanced phenotyping capability with genetic association studies, we suggest that drug efficacy will be better predicted, increasing the likelihood of success in clinical trials when populations are stratified based on genetic variation or designed with multidrug combinations to reach a broader segment of individuals suffering or at risk from NIHL.
Collapse
Affiliation(s)
| | - Xinwen Wang
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, Ohio 44272, USA
| | - Jianxin Bao
- Gateway Biotechnology, St. Louis, Missouri 63132, USA
| |
Collapse
|